Todd Garner: Well, can I not end there, Curt? I just want to be clear for those that are listening, when Curt says that we know they talked about it to their sales force, they talked about their new robot to the sales force. If you listen to what they said public, right, what they’re focused on, what solutions this new product is supposed to address, there was no mention from Intuitive about insufflation. So, this is not a new insufflation robot. They’re solving many other problems that are focused on. I think it is safe to say that insufflation is not on their top-10 list of features of this robot. The shorts on CONMED has made it about insufflation robot. Intuitive has never framed it that way. And Travis, I want to correct something you said so that the audience is not confused, you said is it’s still low-pressure.
It has never been low-pressure. There is zero evidence anywhere that it’s low-pressure. That is an imagination. So, there is no evidence that it’s a low-pressure device. All the evidence would suggest that if they do integrate insufflation, it would indeed be what is referred to as standard insufflation like everything that exists on the market today. That’s what all the evidence points to. There is zero evidence to suggest that this product will compete clinically with AirSeal.
Curt Hartman: And the electronic world of people centered around images of two insufflators hooked up and that’s how they’re going to get to low, I got news for you folks that stuff has been around for a long time. There’s nothing in the market that’s anywhere near AirSeal and has the volume of patients in the clinical studies behind that AirSeal has. So, there’s no one more anxious for the robotic company to get this device in the market so we can demonstrate once and for all. There is no risk here to the AirSeal franchise.
Travis Steed: Great. Thanks for that thorough answer. And sorry, Todd, I may have spoken in the question and got it backwards. But the follow-up question I wanted to ask was on the Capital revenue in the quarter, was a little light versus Street expectations, and I think the businesses you talked about the weakness, and in Q4 were more recurring revenue and not Capital. So just, was Capital light in your mind in Q4? Just curious if there’s any one-time things in the Capital thing to talk about this quarter.
Curt Hartman: Sitting in my chair, I did not think Capital was light in the quarter. I had looked at our business in detail.
Todd Garner: I mean, Capital grew 44% — 43.8% in the quarter, Single-Use Products grew 29.2%. Now, it is, I will — the Ortho business that is having the challenges right now is a higher Capital business than the General Surgery business, it’s kind of 30% typically Capital business. But overall, our Capital growth was faster than our Ortho growth.
Travis Steed: Okay. So, some of the challenges in Q4 were in the Capital side of the business in terms of the Ortho side?
Todd Garner: Yeah, it’s impacted by, sure.
Travis Steed: Okay. No, that’s a helpful clarification. Thank you.
Operator: Thank you. This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to Curt Hartman for any further remarks.
Curt Hartman: Thank you, Jonathan. And I just want to say thank you to everybody today for your time and we look forward to speaking with you during our next earnings call. Thank you.
Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.
